FDA Approves Teleflex's EZPLAZ™ Freeze-Dried Plasma, Transforming Emergency Transfusion Care
核心洞察
The FDA has approved Teleflex's EZPLAZ™ Freeze-Dried Plasma (FDP) for adult transfusion when conventional plasma products are unavailable.
EZPLAZ™ stores at room temperature (2–25°C) with a 12-month shelf life and reconstitutes in approximately 1–2.5 minutes, eliminating freezing and thawing requirements.
The approval comes amid a national blood supply crisis, with the American Red Cross reporting blood donations at a four-year low.
The U.S. Food and Drug Administration has approved EZPLAZ™ Freeze-Dried Plasma (FDP), a novel plasma product developed by Teleflex Incorporated through its Vascular Solutions (搜索) subsidiary. The approval introduces the first freeze-dried plasma option in the United States designed for use when conventional plasma products are unavailable, representing a significant shift in emergency transfusion logistics.
"The approval of EZPLAZ™ FDP marks an important milestone in the availability of freeze-dried plasma in the United States," said Christopher Ross, MD, Global Medical Safety Director and Interim Head of Clinical and Medical Affairs at Teleflex. "Our clinical development program was designed to generate the evidence needed to support the safety and effectiveness of EZPLAZ™ FDP for its approved indication."
Product Characteristics and Logistical Advantages
EZPLAZ™ FDP is distinguished by its room-temperature storage capability, with an approved storage range of 2 to 25°C (36 to 77°F) and a 12-month shelf life. The freeze-dried unit is kitted with all components needed for transfusion, including Sterile Water for Injection (SWFI) for the initial reconstitution step. Reconstitution can be completed in approximately 1 to 2.5 minutes, a dramatic improvement over conventional frozen plasma, which requires time-consuming thawing procedures.
The product is packaged in a plastic bag, offering logistical advantages over traditional glass containers by reducing breakage risk during transport. These features make EZPLAZ™ particularly suited for deployment in combat zones, rural healthcare settings, and disaster response scenarios where cold-chain infrastructure is limited or unavailable.
Clinical Indications
EZPLAZ™ FDP is indicated for transfusion in adults when plasma is required and other plasma products are not available. The approved indications encompass three key clinical scenarios: management of preoperative or bleeding patients requiring replacement of multiple plasma coagulation factors, including those with liver disease (搜索) or disseminated intravascular coagulation (搜索) (DIC); patients undergoing massive transfusion who have clinically significant coagulation deficiencies; and patients taking warfarin who are bleeding or need to undergo an invasive procedure before vitamin K can reverse the warfarin effect, or who require only transient reversal of warfarin.
Safety Considerations and Risk Mitigation
To mitigate the risk of transfusion-related acute lung injury (TRALI), EZPLAZ™ FDP is manufactured exclusively from fresh frozen plasma donated by male-only donors. The product is provided in blood group type AB or type A with low titer Anti-B (less than 1:200 by saline tube method), addressing ABO compatibility concerns.
The prescribing information includes contraindications for patients with a history of hypersensitivity to fresh frozen plasma, liquid plasma, or plasma-derived products including any plasma proteins, as well as patients with IgA deficiency. As with all human plasma-derived products, EZPLAZ™ carries a potential risk of transmitting infectious agents, including viruses, bacteria, and theoretically the variant Creutzfeldt-Jakob disease (vCJD) agent.
The labeling also notes that EZPLAZ™ FDP may be less effective in correcting certain coagulopathies when targeted therapies are available, and clinicians should consider specific coagulation factor concentrates or reversal agents when clinically appropriate. Additionally, the product is not intended for routine volume expansion, and transfusion may not result in meaningful correction of a minimally elevated international normalized ratio (INR), such as values between 1.5 and 1.7.
Addressing a National Blood Supply Crisis
The approval arrives at a critical juncture for the U.S. blood supply. The American Red Cross has reported that blood donations have reached a four-year low, contributing to what has been described as the second national blood supply crisis in U.S. history. The shortage has critically impacted the supply chain of O positive blood across the nation. EZPLAZ™, with its extended shelf life and room-temperature storage, offers a potential buffer against supply chain disruptions that affect conventional plasma products.
Teleflex has been responsible for product development and establishing manufacturing operations to support the submission of the Investigational New Drug (IND) application. Dr. Ross acknowledged the collaborative effort behind the approval: "We are grateful to the investigators, blood donors, study participants, and our government partner whose collaboration made this achievement possible."